

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: RF1/22 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 18.03.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U_{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 2														
(237) anti-streptolysin O (ASLO)					18						17	14	82%	
Samples and groups	[kU/L]													
Sample A2		135	18	13	18						17	14	82%	
(58) Beckman Coulter (AU)		140	1,9	1,4	6	0	CVPG	138	4,3	20%	110	166	6	
(60) Roche		136	14	10	6	0	CVPG	142	4,0	20%	113	171	6	
Other					6	1							5	
-----2x 1, 1x 5, 1x 12, 2x 149-----														
Sample B2		161	22	14	18						17	16	94%	
(58) Beckman Coulter (AU)		165	8,0	4,8	6	0	CVPG	164	3,9	20%	131	197	6	
(60) Roche		168	4,0	2,4	6	0	CVPG	167	4,9	20%	133	201	6	
Other					6	1							5	
-----2x 1, 1x 5, 1x 12, 2x 149-----														
st_kn_p														End of report
														Printed: 28.03.2022